TCM
HLVX

Tekla Capital Management’s HilleVax HLVX Stock Holding History

Tekla Capital Management’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$464K Buy
+27,000
New +$419K 0.02% 147

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Tekla Capital Management's HLVX Position: Q2 2023 in Review

Tekla Capital Management opened a new position in HilleVax (HLVX) in Q2 2023: 27,000 shares worth $464K. The stake represents 0.02% of the portfolio and ranks #147 among its holdings.

54 funds tracked by Wall St. Rank hold HLVX as of Q2 2023.

  • Tekla Capital Management held 27,000 shares of HilleVax worth $464K as of Q2 2023.
  • HilleVax was a new Tekla Capital Management position in Q2 2023.
  • HilleVax made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #147 holding.
  • 54 funds tracked by Wall St. Rank held HilleVax as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.